Why psychiatry needs an honest dose of gentle medicine

被引:4
|
作者
Cosgrove, Lisa [1 ,2 ]
D'Ambrozio, Gianna [1 ,2 ]
Herrawi, Farahdeba [1 ,2 ]
Freeman, Moira [1 ,2 ]
Shaughnessy, Allen [3 ]
机构
[1] Univ Massachusetts Boston, Dept Counseling, Boston, MA 02125 USA
[2] Univ Massachusetts Boston, Sch Psychol, Boston, MA 02125 USA
[3] Tufts Univ, Sch Med, Boston, MA USA
来源
FRONTIERS IN PSYCHIATRY | 2023年 / 14卷
关键词
gentle medicine; polypharmacy; conflicts of interest (COIs); psychotropic medications; pharmaceutical industry; STRUCTURAL COMPETENCE; ANTIPSYCHOTIC USE; PSYCHOPHARMACOLOGY; PHARMACOTHERAPY; ASSOCIATION; DEPRESSION; EFFICACY; STIGMA; HEALTH; TRENDS;
D O I
10.3389/fpsyt.2023.1167910
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The pharmaceutical industry's influence on psychiatric research and practice has been profound and has resulted in exaggerated claims of the effectiveness of psychotropic medications and an under-reporting of harms. After the regulatory approval of fluoxetine, the pharmaceutical industry began promoting (and continues to promote) a chemical imbalance theory of emotional distress. In the last decade, there has been an increased awareness about the limits of this theory and the risks of psychotropic medications. Nonetheless, the medicalization of distress, the sedimented belief in "magic bullets," and the push to "scale up" mental health treatment have contributed to the meteoric rise in the prescription of psychiatric drugs and of polypharmacy. A major premise of this paper is that the conceptual framework of medical nihilism can help researchers and clinicians understand and address the harms incurred by inflated claims of the efficacy of psychotropic medications. We propose that psychiatry, and the mental health field more generally, adopt a model of 'gentle medicine' with regard to both the diagnosis of and treatment for mental health conditions and focus greater attention on the upstream causes of distress.
引用
收藏
页数:7
相关论文
共 50 条